Main content

    Hematologic Oncology Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov



    Multiple Myeloma  |  Myelodysplastic Syndrome  |  Myelofibrosis


    Active Trials

    Multiple Myeloma

    Title: A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
    Decscription: This randomized phase II trial studies how well two doses of carfilzomib work with dexamethasone in treating patients with relapsed or refractory multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have a confirmed diagnosis of symptomatic multiple myeloma and must be relapsed or refractory
    Status: Contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1304

    Title: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
    Decscription: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with symptomatic standard-risk multiple myeloma (SR-MM)
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E1A11

    Title: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    Decscription: This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E3A06

    Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
    Description: This study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma
    Investigator (Santa Rosa): Eric Dean, MD
    Eligibility: Subjects, 18 y/o and older, with a documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study CELGN-4047MM-007

    Back to top

    Myelodysplastic Syndrome

    Title: A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes
    Description: This study is to compare the overall response rate (inclusive of complete response, partial response and hematologic improvement) per IWG 2006 criteria in patients with higher risk MDS treated with azacitidine with or without deferasirox achieved over the course of one year. Hematologic improvement must be maintained for at least 8 weeks
    Investigator (Santa Rosa): Eric Dean, MD
    Eligibility: Subjects, 18 y/o and older, with a higher risk MDS with a blast count < 20% at the time of screening IPSS Int-2 or High Risk Serum Ferritin ≥ 300 ng/mL at screening
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Exjade

    Back to top

    Myelofibrosis

    Title: An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50,000 to 100,000
    Description: To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in patients with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels
    Investigator (Santa Rosa): Eric Dean, MD
    Eligibility: Subjects, 18 y/o and older, with a diagnosis of PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study INCYTE 18424

    • updated January 2015

    Back to top